A new fertility treatment is showing encouraging results for couples struggling to conceive. Femasys has published results from its clinical trial of FemaSeed, a new approach to artificial insemination, in the Journal of Gynecology & Reproductive Medicine.
“We are grateful for the renowned investigators from leading academic medical centers and private practices that participated in this landmark trial,” stated Kathy Lee-Sepsick, CEO of Femasys. “Our impressive pivotal data for FemaSeed, showed significantly improved pregnancy rates, over double that of intrauterine insemination (IUI) for low male sperm count, a primary or contributing cause of infertility for approximately 50% of couples. FemaSeed offers a highly effective, first-line solution for women and couples seeking a less invasive and more affordable option than in vitro fertilization (IVF).”
The study’s results were encouraging: 26.3% of participants achieved pregnancy, and the treatment showed a 17.5% success rate per attempt. These numbers significantly exceeded expectations, showing more than double the success rate of traditional methods. The treatment was found to be safe, with side effects similar to standard artificial insemination procedures. Importantly, most patients said they would recommend FemaSeed to others.
FemaSeed works by placing sperm directly in the fallopian tube, where pregnancy naturally begins. This targeted approach may help more sperm reach the egg, potentially improving the chances of pregnancy, especially in cases where lower sperm count is a factor.
The treatment has already received approval from health authorities in multiple countries – the U.S. Food and Drug Administration approved it in September 2023, Canada gave approval in April 2023, and Europe authorized its use in June 2024.
